Carlo Guarnieri

Carlo Guarnieri

Auto-generated profile, based on publicly available information

Carlo Guarnieri

BioEngLab, Health Science and Technology - Interdepartmental Center for Industrial Research (HST-CIRI), University of Bologna, Ozzano Emilia, BO, Italy

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2014 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
FBFrancesca Bonafè
Francesca Bonafè
Marco GovoniMarco Govoni
Marco Govoni
EGEmanuele GIORDANO
Emanuele GIORDANO
CCClaudio Marcello Caldarera
Claudio Marcello Caldarera
CGCarlo Guarnieri
Carlo Guarnieri
CMClaudio Muscari
Claudio Muscari
Hyaluronan (HA) is abundantly expressed in several human tissues and a variety of roles for HA has been highlighted. Particularly relevant for tissue repair, HA is actively produced during tissue injury, as widely evidenced in wound healing investigations. In the heart HA is involved in physiological functions, such as cardiac development during embryogenesis, and in pathological conditions including atherosclerosis and myocardial infarction. Moreover, owing to its relevant biological properties, HA has been widely used as a biomaterial for heart regeneration after a myocardial infarction. Indeed, HA and its derivatives are biodegradable and biocompatible, promote faster healing of injured tissues, and support cells in relevant processes including survival, proliferation, and differentiation. Injectable HA-based therapies for cardiovascular disease are gaining growing attention because of the benefits obtained in preclinical models of myocardial infarction. HA-based hydrogels, especially as a vehicle for stem cells, have been demonstrated to improve the process of cardiac repair by stimulating angiogenesis, reducing inflammation, and supporting local and grafted cells in their reparative functions. Solid-state HA-based scaffolds have been also investigated to produce constructs hosting mesenchymal stem cells or endothelial progenitor cells to be transplanted onto the infarcted surface of the heart. Finally, applying an ex-vivo mechanical stretching, stem cells grown in HA-based 3D scaffolds can further increase extracellular matrix production and proneness to differentiate into muscle phenotypes, thus suggesting a potential strategy to create a suitable engineered myocardial tissue for cardiac regeneration.

1 January 2013 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
CMClaudio Muscari
Claudio Muscari
EGEmanuele GIORDANO
Emanuele GIORDANO
FBFrancesca Bonafè
Francesca Bonafè
Marco GovoniMarco Govoni
Marco Govoni
APAlice Pasini
Alice Pasini
CGCarlo Guarnieri
Carlo Guarnieri
The efficiency of regenerative medicine can be ameliorated by improving the biological performances of stem cells before their transplantation. Several ex-vivo protocols of non-damaging cell hypoxia have been demonstrated to significantly increase survival, proliferation and post-engraftment differentiation potential of stem cells. The best results for priming cultured stem cells against a following, otherwise lethal, ischemic stress have been obtained with brief intermittent episodes of hypoxia, or anoxia, and reoxygenation in accordance with the extraordinary protection afforded by the conventional maneuver of ischemic preconditioning in severely ischemic organs. These protocols of hypoxic preconditioning can be rather easily reproduced in a laboratory; however, more suitable pharmacological interventions inducing stem cell responses similar to those activated in hypoxia are considered among the most promising solutions for future applications in cell therapy. Here we want to offer an up-to-date review of the molecular mechanisms translating hypoxia into beneficial events for regenerative medicine. To this aim the involvement of epigenetic modifications, microRNAs, and oxidative stress, mainly activated by hypoxia inducible factors, will be discussed. Stem cell adaptation to their natural hypoxic microenvironments (niche) in healthy and neoplastic tissues will be also considered.

10 December 2015 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
Marco GovoniMarco Govoni
Marco Govoni
CMClaudio Muscari
Claudio Muscari
JLJoseph Lovecchio
Joseph Lovecchio
CGCarlo Guarnieri
Carlo Guarnieri
EGEmanuele GIORDANO
Emanuele GIORDANO

6 July 2010 in Open Heart Failure Journal
Verified
Journal Article
Closed access
EGEmanuele GIORDANO
Emanuele GIORDANO
FFFlavio Flamigni
Flavio Flamigni
CGCarlo Guarnieri
Carlo Guarnieri
CMClaudio Muscari
Claudio Muscari
Carla PIGNATTICarla PIGNATTI
Carla PIGNATTI
CCClaudio Marcello Caldarera
Claudio Marcello Caldarera

20 September 2012 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
APAlice Pasini
Alice Pasini
PIPaolo Iorio
Paolo Iorio
EBEmanuela Bianchi
Emanuela Bianchi
SCSerenella Cerasoli
Serenella Cerasoli
ACAnna M. Cremonini
Anna M. Cremonini
EGEmanuele GIORDANO
Emanuele GIORDANO
We previously described a cohort of grade II oligodendroglioma (OII) patients, in whom the loss of heterozygosity (LOH) 19q was present in the subgroup at a higher risk of relapse. In this study, we evaluated the CpG methylation of the putative tumor suppressor epithelial membrane protein 3 (EMP3, 19q13.3) gene promoter in the same OII cohort, to investigate whether a correlation could be found between EMP3 cytogenetic and epigenetic loss and higher risk of relapse. Twenty-three tumor samples from OII patients were collected over a period of 10 years. Seventeen glioblastoma (GBM) samples (2 of which were relapses) were collected from 15 patients. The EMP3, O6-methylguanine methyltransferase (MGMT) and cyclooxygenase 2 (COX2) promoter methylation, evaluated by methylation-specific PCR, and the isocitrate dehydrogenase 1 (IDH1) mutation, identified by sequencing, were compared between the OII and GBM histotypes. The EMP3 promoter methylation was correlated with the analysis of LOH 19q, performed by microsatellite amplification, in OII patients. Disease progression-free interval was evaluated in the OII patients with the EMP3 methylation with either LOH 19q or conserved chromosome 19 arms. The EMP3 and MGMT promoter methylation was more frequent in OII than in GBM patients, and the IDH1 mutation was absent in GBM. The COX2 promoter was unmethylated in both histotypes. Both LOH+/- 19q OII patients showed EMP3 hypermethylation. Concomitant LOH 19q and EMP3 gene promoter methylation was observed in the OII patients at a higher risk of relapse. Our results suggest that a total (cytogenetic and epigenetic) functional loss of both EMP3 alleles accounts for the reduced disease progression-free interval in OII patients. Although the small sample size limits the strength of this study, our results support testing this hypothesis in larger cohorts of patients, considering the methylation of the EMP3 gene promoter together with LOH 19q as an indication for treatment with adjuvant therapy ab initio in order to improve the overall survival of OII patients.

1 January 1988
Verified
Book Chapter
Closed access
PDF file
FFFlavio Flamigni
Flavio Flamigni
FMFlavio Meggio
Flavio Meggio
Sandra MarmiroliSandra Marmiroli
Sandra Marmiroli
CGCarlo Guarnieri
Carlo Guarnieri
LPLuigi Pinna
Luigi Pinna
CCClaudio M. Caldarera
Claudio M. Caldarera